Probiotics in the treatment of infantile colic: a meta-analysis of randomized controlled trials.

Introduction: Introduction: infantile colic has always been a problem for caregivers, and research on probiotics in treating and preventing infant colic is still controversial. Material and methods: trials were performed before November 2021 and retrieved from the PubMed, Web of Science, The Cochrane Library, Medline, and Google Scholar databases. Data extraction and quality evaluation of the trials were performed independently by two investigators. A meta-analysis was performed using Review Manager 5.3. It includes nine randomized controlled trials in 587 infants with colic. Results: eight of these experiments described probiotics for the prevention and treatment of intestinal colic in infants, with 228 in the probiotics group and 227 in the placebo group, with a total effective rate (RR = 1.88, 95 % CI: 1.61 to 2.19, p < 0.00001). Conclusion: probiotics may improve therapeutic and preventive effects, especially within four weeks of probiotic treatment.

Introducción: Introducción: el cólico infantil siempre ha sido un problema para los cuidadores y la investigación sobre los probióticos para tratar y prevenir el cólico infantil sigue siendo controvertida. Material y métodos: los ensayos se realizaron antes de noviembre de 2021 y se recuperaron de las bases de datos PubMed, Web of Science, The Cochrane Library, Medline y Google Scholar. Dos investigadores realizaron de forma independiente la extracción de datos y la evaluación de la calidad de los ensayos. Se realizó un metaanálisis utilizando Review Manager 5.3. Incluye nueve ensayos controlados aleatorios en 587 lactantes con cólicos. Resultados: ocho de estos experimentos describieron probióticos para la prevención y el tratamiento del cólico intestinal en lactantes, con 228 en el grupo de probióticos y 227 en el grupo de placebo, con una tasa efectiva total (RR = 1,88, IC del 95 %: 1,61 a 2,19, p < 0,00001). Conclusión: los probióticos pueden mejorar los efectos terapéuticos y preventivos, especialmente dentro de las cuatro semanas posteriores al tratamiento con los mismos.

Probiotics in the treatment of infantile colic: a meta-analysis of randomized controlled trials / Probióticos en el tratamiento del cólico infantil: un metaanálisis de ensayos controlados aleatorios

Introduction: infantile colic has always been a problem for caregivers, and research on probiotics in treating and preventing infant colic is still controversial. Material and methods: trials were performed before November 2021 and retrieved from the PubMed, Web of Science, The Cochrane Library, Medline, and Google Scholar databases. Data extraction and quality evaluation of the trials were performed independently by two investigators. A meta-analysis was performed using Review Manager 5.3. It includes nine randomized controlled trials in 587 infants with colic. Results: eight of these experiments described probiotics for the prevention and treatment of intestinal colic in infants, with 228 in the probiotics group and 227 in the placebo group, with a total effective rate (RR = 1.88, 95 % CI: 1.61 to 2.19, p < 0.00001). Conclusion: probiotics may improve therapeutic and preventive effects, especially within four weeks of probiotic treatment. (AU)

Introducción: el cólico infantil siempre ha sido un problema para los cuidadores y la investigación sobre los probióticos para tratar y prevenir el cólico infantil sigue siendo controvertida. Material y métodos: los ensayos se realizaron antes de noviembre de 2021 y se recuperaron de las bases de datos PubMed, Web of Science, The Cochrane Library, Medline y Google Scholar. Dos investigadores realizaron de forma independiente la extracción de datos y la evaluación de la calidad de los ensayos. Se realizó un metaanálisis utilizando Review Manager 5.3. Incluye nueve ensayos controlados aleatorios en 587 lactantes con cólicos. Resultados: ocho de estos experimentos describieron probióticos para la prevención y el tratamiento del cólico intestinal en lactantes, con 228 en el grupo de probióticos y 227 en el grupo de placebo, con una tasa efectiva total (RR = 1,88, IC del 95 %: 1,61 a 2,19, p < 0,00001). Conclusión: los probióticos pueden mejorar los efectos terapéuticos y preventivos, especialmente dentro de las cuatro semanas posteriores al tratamiento con los mismos. (AU)

Establishment of novel rat models for premalignant breast disease.

BACKGROUND: Breast cancer has become one of the most common malignant tumors among females over the past several years. Breast carcinogenesis is a continuous process, which is featured by the normal epithelium progressing to premalignant lesions and then to invasive breast cancer (IBC). Targeting premalignant lesions is an effective strategy to prevent breast cancer. The establishment of animal models is critical to study the mechanisms of breast carcinogenesis, which will facilitate research on breast cancer prevention and drug behaviors. In this study, we established a feasible chemically-induced rat model of premalignant breast cancer. METHODS: Following the administration of the drugs (carcinogen, estrogen, and progestogen) to Sprague-Dawley (SD) rats, tumors or suspicious tumors were identified by palpation or ultrasound imaging, and were surgically excised for pathological evaluation. A series of four consecutive steps were carried out in order to determine the carcinogen: 7,12-dimethylbenzaanthracene (DMBA) or 1-methyl-1-nitrosourea, the route of carcinogen administration, the administration period of estrogen and progestogen, and the DMBA dosage. RESULTS: Stable premalignant lesions can be induced in SD rats on administration of DMBA (15 mg/kg, administered three times) followed by administration of female hormones 5-day cycle. RESULTS: were confirmed by ultrasound and palpation. CONCLUSION: Under the premise of drug dose and cycle, DMBA combined with estrogen and progestogen can be used as a SD rat model for breast premalignant lesions.

VEGF-C antisense oligoxydeonucleotide suppression of invasive ability of the A-549 lung carcinoma cell line.

OBJECTIVE: Vascular endothelial growth factor C (VEGF-C), a member of the VEGF family, has been reported to promote angiogenesis and tumor cell growth. In this study, we analyzed inhibitory action of a VEGF-C antisense oligoxydeonucleotide (ASODN) on a lung carcinoma cell line A-549 and its invasive ability in vitro. METHODS: Liposomes, liposome-mediated sense oligoxydeonucleotide (SODN) and ASODN were transfected into A-549 cells, with a blank control group. The expression of VEGF-C was examined by western blotting and invasive ability of cells was detected at four levels. RESULTS: Lower expression of VEGF-C and lower invasive ability to recombinate basal membranes were apparent in the ASOND group (P<0.01). However, there were no significant differences among the other three groups (P>0.05). In the invasion assay, the number of transmembrane cells was significantly reduced in the ASODN group after 48 hours (58.6±9.2 P<0.01), but there was no variation among control, LIP and SOND groups (132.5±15.6, 129.7±16.1, 118.2±12.5, P>0.05). CONCLUSIONS: VEGF-C ASODN can downregulate the expression of VEGF-C in cell lines and can obviously inhibit invasive ability in vitro.